David M Lederman Net Worth

The estimated Net Worth of David M Lederman is at least $368 Million dollars as of 6 June 2005. David Lederman owns over 2,000 units of Abiomed stock worth over $364,244,070 and over the last 21 years David sold ABMD stock worth over $3,723,090.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Lederman ABMD stock SEC Form 4 insiders trading

David has made over 80 trades of the Abiomed stock since 2004, according to the Form 4 filled with the SEC. Most recently David sold 2,000 units of ABMD stock worth $18,740 on 6 June 2005.

The largest trade David's ever made was selling 5,000 units of Abiomed stock on 31 May 2005 worth over $49,700. On average, David trades about 4,084 units every 6 days since 2003. As of 6 June 2005 David still owns at least 955,971 units of Abiomed stock.

You can see the complete history of David Lederman stock trades at the bottom of the page.

What's David Lederman's mailing address?

David's mailing address filed with the SEC is C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS, MA, 01923.

Insiders trading at Abiomed

Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose und David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.

What does Abiomed do?

Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.

Complete history of David Lederman stock trades at Abiomed

Abiomed executives and stock owners

Abiomed executives and other stock owners filed with the SEC include:

• Michael Minogue,
  Chairman of the Board, President, Chief Executive Officer
• Todd Trapp,
  Chief Financial Officer, Vice President
• Andrew Greenfield,
  Vice President, Chief Commercial Officer
• David Weber,
  Chief Operating Officer, Senior Vice President
• Michael R. Minogue,
  Chairman, CEO & Pres
• Michael Howley,
  Vice President and General Manager, Global Sales
• Todd A. Trapp,
  CFO & VP
• Dr. David M. Weber,
  Sr. VP & COO
• Marc A. Began,
  VP, Gen. Counsel & Sec.
• Andrew J. Greenfield,
  VP & Chief Commercial Officer
• Dorothy Puhy,
  Lead Independent Director
• Paul Thomas,
  Independent Director
• Martin Sutter,
  Independent Director
• Jeannine Rivet,
  Independent Director
• Christopher Van Gorder,
  Independent Director
• Eric Rose,
  Independent Director
• Marc Began,
  Vice President, General Counsel, Secretary
• Karen Mahoney,
  Head of Global HR
• Michael G. Howley,
  VP & GM of Global Sales
• Sarah Karr,
  Communications Mang.
• Ingrid Goldberg Ward,
  Director of Investor Relations
• Dr. Thorsten Siess Ph.D.,
  VP & CTO
• Henri A Termeer,
  Director
• Gorder Chris Van,
  Director
• William J Bolt,
  SVP, DA and QA
• Michael John Tomsicek,
  Vice President, CFO
• W Gerald Austen,
  Director
• Myron L Rolle,
  Director
• Louis E Lataif,
  Director
• Robert Bowen,
  Chief Financial Officer
• Ronald W Dollens,
  Director
• Daniel J Sutherby,
  CFO
• Inc Abiomed,
  Director
• Connell Desmond Jr O,
  Director
• Paul Fireman,
  Director
• Javier Jimenez,
  VP Operations
• Anthony W Bailey,
  VP, Business Development
• David M Lederman,
  Chairman, CEO & President
• Charles B Haaser,
  Principal Financial Officer
• Eugene D Rabe,
  SVP, Global Sales & Services
• Christopher D Macdonald,
  SVP Global Sales
• Sheila Marie Flaherty,
  VP, General Counsel
• Robert T V Kung,
  SVP, Chief Scientific Officer
• Edward E Berger,
  VP, Strat. Plan & Ext. Comm.
• Patricia A. Fitch,
  Vice President of Sales
• Raymond J Kelley,
  VP Marketing
• David Gottlieb,
  Director
• John F Obrien,
  Director
• Gary Stickel,
  VP of HR
• Karim Benali,
  VP Product Development
• Robert Farra,
  VP Engineering & Manufacturing
• Stephen C Mc Evoy,
  VP and General Counsel
• Paula A Johnson,
  Director